Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $478.67

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned an average rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twenty-three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $478.6688.

A number of equities analysts recently issued reports on ALNY shares. Piper Sandler reiterated an “overweight” rating and issued a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday. Citigroup increased their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a report on Monday, October 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 10th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director owned 775 shares of the company’s stock, valued at $362,390. This trade represents a 95.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ALNY. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $662,837,000. Holocene Advisors LP purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $194,616,000. Orbis Allan Gray Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $162,577,000. Finally, Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $434.07 on Friday. The stock has a 50-day moving average price of $460.00 and a 200-day moving average price of $372.32. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a market cap of $56.90 billion, a PE ratio of -175.74 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating the consensus estimate of $1.39 by $1.51. The company had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $943.37 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue for the quarter was up 149.3% compared to the same quarter last year. During the same period last year, the business posted ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.